Advertisement
UK markets close in 5 hours 43 minutes

  • FTSE 100

    8,296.87
    +83.38 (+1.02%)
     

  • FTSE 250

    20,389.46
    +224.92 (+1.12%)
     

  • AIM

    777.10
    +5.57 (+0.72%)
     

  • GBP/EUR

    1.1656
    -0.0004 (-0.03%)
     

  • GBP/USD

    1.2539
    -0.0024 (-0.19%)
     

  • Bitcoin GBP

    51,225.95
    -747.21 (-1.44%)
     

  • CMC Crypto 200

    1,333.76
    -31.36 (-2.30%)
     

  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     

  • DOW

    38,852.27
    +176.59 (+0.46%)
     

  • CRUDE OIL

    78.52
    +0.04 (+0.05%)
     

  • GOLD FUTURES

    2,323.70
    -7.50 (-0.32%)
     

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • DAX

    18,283.76
    +108.55 (+0.60%)
     

  • CAC 40

    8,018.12
    +21.48 (+0.27%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

BTG gets triple dose of good news on new products

Reuters - UK Focus

(Adds comment from CEO and analyst, latest shares)

LONDON, Dec 14 (Reuters) - Specialist medicine company BTG (Other OTC: BTGYY - news) received a triple dose of good news on Monday as U.S (Other OTC: UBGXF - news) . regulators approved two new treatments and a clinical trial of a novel lung device produced positive results.

U.S. green lights for Vistogard and Lumi, for chemotherapy overdoses and tumours, and the success of PneumRx coils in severe emphysema may help counter recent disappointment over sales of BTG (LSE: BTG.L - news) 's varicose vein treatment Varithena.

BTG Chief Executive Louise Makin said the positive developments demonstrated the company was delivering on its strategy to become a world-leading specialist healthcare business.

ADVERTISEMENT

The success of PneumRx coils removes a key remaining risk to the launch of the product in the United States, where it will now be filed for approval in mid-2016.

Although Deutsche Bank analyst Richard Parkes said the benefit appeared only modest in the PneumRx coils study, as measured by the main outcome, secondary clinical results were strong.

BTG shares, which have underperformed in recent months on concerns about sales of Varithena, were 0.8 percent higher at 630 pence by 1110 GMT. (Reporting by Ben Hirschler; Editing by Louise Heavens and Mark Potter)